Projektportal

Startsida Om denna webbplats

Logga in

Theranostics for prostate cancer: Combined targeted radionuclide imaging and therapy

Terrmin

HT24

Beskrivning

There is a clinical need to improve further therapy of prostate cancer PCa. Research i Theranostics group provides scientific rationale for the use of theranostics for therapy of prostate cancer. The theranostics approach includes radionuclide imaging of molecular targets, i.e. receptors and antigens closely associated with prostate cancer progression (e.g. prostate-specific membrane antigen (PSMA), gastrin-releasing peptide receptor (GRPR) in combination with therapy specific to these targets.
The aim of our research is to obtain knowledge permitting the use of molecular targeting for radionuclide diagnostic and therapy of disseminated prostate cancer. We develop and evaluate short radiolabelled synthetic peptides targeting GRPR and PSMA as well as bispecific peptides targeting simultaneously PSMA and GRPR for imaging and therapy of prostate cancer metastases. we evaluate factors influencing targeting properties and therapeutic efficacy of scaffold protein-based constructs against RTK for targeting therapy of prostate cancer.

Huvudområde

Läkemedelsutveckling

Ämne

Molekylär avbildning

Typ

Laborativ studie

Företag

Uppsala University

Ort/Plats

Uppsala

Handledarens namn

Anna Orlova

Handledarens e-post

anna.orlova@ilk.uu.se

Institution

Institutionen för Läkemedelskemi

Program

Masterprogram i läkemedelsutveckling

Kurs

Degree project in Drug Discovery and Development 45 c - 3FK044

Omfattning/hp

45hp